IMMUNIC, INC. 8-K

What Happened Immunic, Inc. (IMUX) announced that on June 29, 2026 Tamar Howson resigned from the Board of Directors and from the Board’s Compensation Committee as she transitions into retirement. The company stated her resignation was not due to any disagreement with the Company on operations, policies, or practices. On July 5, 2026, following a recommendation from the Nominating and Corporate Governance Committee, the Board appointed Erik Lundgren, Immunic’s Chief Executive Officer, as a Class II director effective immediately, to serve until the 2028 annual meeting or until his successor is elected.

Key Details

• Tamar Howson resigned from the Board and Compensation Committee on June 29, 2026; resignation not due to any disagreement with the company.
• Erik Lundgren was appointed to the Board on July 5, 2026 as a Class II director, term through the 2028 annual meeting.
• Mr. Lundgren will not receive additional compensation for his director service and has not been assigned to any Board committees.
• Mr. Lundgren is party to an employment agreement previously disclosed in Immunic’s May 27, 2026 Form 8‑K; no other transactions requiring Item 404 disclosure were reported.

Why It Matters This filing documents a change in Immunic’s board composition: a long-serving director retired and the company’s CEO joined the Board. For investors, key facts are the dates of the changes, that the CEO’s board role is unpaid beyond his existing employment compensation, and that the company confirmed the resignation was not due to any dispute. These are governance updates you may want to note alongside other corporate developments.